Probiotics and Antimicrobial Proteins Microbiology
Environmental Microbiomes as Sources of Postbiotic Therapeutics: A One Health Perspective on Translational Applications
Abstract
Environmental microbiomes are reservoirs of specialized microorganisms with implications for ecosystem functionality, host health, and therapeutic discovery. Soil, marine, plant-associated, wastewater, freshwater, and extreme-environment microbiomes contain communities capable of producing bioactive metabolites and functional biomolecules. Postbiotics—non-viable microorganisms and their functional components that confer health benefits—offer potential advantages in stability, safety, scalability, and pharmaceutical development. This review examines environmental microbiomes as sources of postbiotic therapeutics within a One Health framework. A critical integrative translational review synthesized literature on environmental microbiomes, postbiotic diversity, molecular mechanisms, therapeutic applications, technological advances, and barriers to clinical translation. Evidence was organized across ecological sources, postbiotic classes, human-health applications, discovery platforms, pharmaceutical development, and translational challenges. Environmental microbiomes represent chemically and functionally diverse reservoirs of postbiotic candidates shaped by ecological adaptation, microbial competition, and environmental selection. Major classes—including short-chain fatty acids, bacteriocins, extracellular vesicles, indole and tryptophan metabolites, exopolysaccharides, and microbial/lytic enzymes—act through receptor signaling, immune modulation, barrier protection, antimicrobial activity, metabolic regulation, intercellular communication, and enzymatic target modification. Metagenomics, metabolomics, artificial intelligence, synthetic biology, organoid and microfluidic models, advanced delivery systems, and biomanufacturing increasingly enable discovery and development. However, reproducibility, microbiome variability, manufacturing scalability, regulatory standardization, cost, and equitable translation remain barriers. Environmental microbiomes provide important reservoirs for postbiotic discovery. Integrating ecological microbiology with multi-omics, computational innovation, pharmaceutical engineering, and human-relevant validation could accelerate development of defined, reproducible, and scalable postbiotic therapeutics. Preserving microbial ecosystem diversity is relevant to environmental sustainability and future microbiome-derived therapeutic innovation within One Health medicine.